Secondary analysis of trials in 4057 COVID-19 outpatients: casirivimab plus imdevimab vs placebo cut hospitalisation or death regardless of atopy (HR 0.26 no atopy, 0.17 atopy without asthma, 0.32 asthma only).
Secondary analysisn = 4,057
Chen et al. Effect of background asthma and atopic conditions on prophylaxis and treatment of COVID-19 infection